Reappraising antiangiogenic therapy for breast cancer-Reference-Cited by-同舟云学术

Reappraising antiangiogenic therapy for breast cancer

Published:2011-10 Issue: Volume:20 Page:S56-S60
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Kerbel Robert S.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference59 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Af;Hurwitz;Engl J Med,2004

2. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Af;Miller;EnglJ Med,2007

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Af;Sandier;EnglJ Med,2006

4. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J din;Rini;Oncol,2010

5. The bevacizumab experience in advanced renal cell carcinoma;Harshman;Onco Targets Ther,2010

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress in tumor angiogenesis and drug resistance in breast cancer;Cancer Biology & Medicine;2024-06-25

2. Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach;Cancers;2022-10-19

3. The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment;Frontiers in Immunology;2022-02-23

4. Vascular Co-option in the Brain Tumor Microenvironment;Biomarkers of the Tumor Microenvironment;2022

5. Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line;Breast Cancer;2021-11-01